| Literature DB >> 20017951 |
Chien-Shun Chiou1, Jui-Ming Lin, Cheng-Hsun Chiu, Chi-Hong Chu, Shu-Wun Chen, Yung-Fu Chang, Bor-Chun Weng, Jwu-Guh Tsay, Chyi-Liang Chen, Chien-Hsing Liu, Chishih Chu.
Abstract
BACKGROUND: Nontyphoidal Salmonella is the main cause of human salmonellosis. In order to study the prevalent serogroups and serovars of clinical isolates in Taiwan, 8931 Salmonellae isolates were collected from 19 medical centers and district hospitals throughout the country from 2004 to 2007. The pulsed-field eletrophoresis types (PFGE) and antibiotic resistance profiles of Salmonella enterica serovars Bareilly (S. Bareilly) and Braenderup (S. Braenderup) were compared, and multi-drug resistance (MDR) plasmids were characterized.Entities:
Mesh:
Year: 2009 PMID: 20017951 PMCID: PMC2806260 DOI: 10.1186/1471-2180-9-264
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Prevalence of Salmonella serogroups and their main serovars isolated from human from 2004 to 2007.
| Serogroup/Serovar | Number of isolates | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2004 | 2005 | 2006 | 2007 | Total | 2004 | 2005 | 2006 | 2007 | Total | |
| Serogroup B | 1133 | 1045 | 938 | 854 | 3970 | 44.3 | 46.9 | 44.0 | 42.4 | 44.5 |
| | 571 | 551 | 441 | 412 | 1975 | 22.3ab | 24.7a | 20.7b | 20.4b | 22.1ab |
| | 287 | 183 | 242 | 168 | 880 | 11.2 | 8.2 | 11.4 | 8.3 | 9.9 |
| Serogroup C1 | 364 | 229 | 234 | 184 | 1101 | 14.2 | 10.3 | 11.0 | 9.1 | 11.3 |
| | 111 | 65 | 30 | 17 | 223 | 4.3 | 2.9 | 1.41 | 0.84 | 2.50 |
| | 96 | 46 | 66 | 32 | 240 | 3.8 | 2.1 | 3.1 | 1.6 | 2.7 |
| | 54 | 41 | 47 | 54 | 196 | 2.1 | 1.8 | 2.2 | 2.7 | 2.2 |
| | 43 | 34 | 33 | 19 | 129 | 1.7 | 1.5 | 1.6 | 0.9 | 1.4 |
| Other serovars1 | 60 | 43 | 58 | 62 | 223 | 2.3 | 1.9 | 2.7 | 3.1 | 2.5 |
| Serogroup C2-C3 | 231 | 246 | 239 | 228 | 944 | 9.0 | 11.0 | 11.2 | 11.3 | 10.6 |
| | 144 | 137 | 135 | 147 | 563 | 5.6 | 6.1 | 6.3 | 7.3 | 6.3 |
| | 87 | 109 | 104 | 81 | 381 | 3.4 | 4.9 | 4.9 | 4.0 | 4.3 |
| Serogroup D | 597 | 550 | 583 | 609 | 2339 | 23.3 | 24.7 | 27.4 | 30.2 | 26.2 |
| | 586 | 543 | 567 | 582 | 2278 | 22.9c | 24.4bc | 26.6ab | 28.9a | 25.5 |
| Serogroup E1 | 122 | 76 | 64 | 70 | 332 | 4.8 | 3.4 | 3.0 | 3.5 | 3.7 |
| | 94 | 61 | 556 | 62 | 273 | 3.7 | 2.7 | 2.6 | 3.1 | 3.1 |
| Sum3 | 2447 | 2147 | 2058 | 1954 | 8736 | 95.6 | 96.3 | 96.6 | 96.5 | 96.3 |
| Total | 2,557 | 2,228 | 2,131 | 2,015 | 8,931 | |||||
1Other serogroup C1 serovars include are mainly S. Infantis, S. Potsdam, S. Mbandaka, and S. Montevideo.
2Numbers in parenthesis indicate the percentage of isolates of a C1 serovar over total serogroup C1 isolates.
3Sum is the total number of serogroup B, C1, C2-C3, D, and E isolates.
abcDifferent letters indicate significant difference between years.
Age prevalence of patient infected by S. Bareilly and S. Braenderup
| Rate (%) of each age group | ||||
|---|---|---|---|---|
| Serovar | 0 ~ 4 | 5 ~ 12 | 13 ~ 50 | > 50 |
| 49.0b | 9.8 | 9.8 | 31.4b | |
| 68.9a | 8.9 | 13.3 | 8.9a | |
abDifferent letters indicate significant difference between S. Bareilly and S. Braenderup (Pp<0.05).
Figure 1Dendrograms were constructed by PFGE-. The dendrograms were generated by the unweighted pair group method with arithmetic mean (UPGMA) using the Dice-predicted similarity value of two patterns. The BioNumerics version 4.5 statistics program was used with settings of 1.0% optimization and 0.7% tolerance. Symbols of black square and white square represent resistant and susceptible respectively. Plasmids were separated into four groups by size. Ex, 1, 1, 1, 3 indicates that this strain harbored 6 plasmids, one is >90 kb, one is from >50 to <90 kb, one is from >6.6 to <50 kb, and three are <6.6 kb.
Characteristics of MDR plasmids from 17 S. Braenderup isolates.
| Antimicrobial resistance gene | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strains | Plasmid | Plasmid | Conjugation rate | Class I integron | IS | Month of isolation | Number of isolates | |||||
| 1a | ACKTSSxt | + | + | - | 137.4 | 4.22 × 10-6 | F1A/1B | + | ND | 2004.8 | 2 | |
| | ACKSxtT | + | ||||||||||
| 1a | ACKSSxtT | + | + | - | 137.4 | 6.04 × 10-6 | F1A/1B | + | ND | 2004.8 | ||
| | ACKSxtT | + | ||||||||||
| 1b | ASSxt | + | + | - | 122.6 | 8.25 × 10-6 | F1A/1B | + | ND | 2004.8 | 1 | |
| | ASxt | + | ||||||||||
| 1d | ASSxtT | + | + | - | 102.5 | -- | F1A/1B | + | ND | 2004.7 | 7 | |
| | ASxt | + | ||||||||||
| 1e | ASSxtT | + | + | - | 99.1 | - | F1A/1B | + | ND | 2005.4 | 3 | |
| | ASxt | + | ||||||||||
| 1g | ASxtT | - | + | - | 104.4 | - | F1A/1B | - | ND | 2005.1 | 1 | |
| | ASxt | + | ||||||||||
| ACSSxtT | + | + | + | + | ND | 2004.7 | ||||||
| | A | - | - | + | 75.5 | 8.41 × 10-2 | IncI1 | - | - | 1 | ||
| | 1f | ACSxtT | + | + | - | 127.8 | - | F1A/1B | + | + | 1 | |
| ASSxtT | + | + | + | + | ND | 2005.9 | ||||||
| | 2a | A | - | - | + | 75.5 | 8.66 × 10-2 | IncI1 | - | - | 1 | |
| | 1d | ASxt | + | + | - | 102.5 | ND | F1A/1B | + | + | 1 | |
| ASSxtT | + | + | + | + | ND | 2005.5 | ||||||
| | 2b | A | - | - | + | 85 | 1.28 × 10-1 | IncI1 | - | - | 1 | |
| | 1c | ASxt | + | + | - | 104.8 | - | F1A/1B | + | + | 1 | |
1Abbreviation: A, ampicillin; C, chloramphenicol; K, kanamycin; S, streptomycin; Sxt, trimethoprim-sulfamethoxazole; T, tetracycline.
2ND, not determined; +, conjugative; -, .non-conjugative.
3Inc, plasmid incompatibility group.
4Other 6 isolates 30 from 2005/2, 31 from 2004/10, 35 from 2005/7, 37 from 2005/3, 44 from 2004/6, and 82 from 2004/7 were not tested for conjugation.
5Other 2 isolates 15 from 2005/5 and 21 from 2004/9 were not tested for conjugation.
Figure 2. M1: HindIII-digested lambda DNA size marker. M2: 1 kb size marker.
Figure 3PCR amplification of IS. (A) Primer design. Symbols of arrow and dashed arrow represent IS26in primers and IS26out primers, respectively. (B) PCR products amplified by IS26in primers. (C) PCR products amplified by IS26out primers. M1: 100-bp size marker. N: negative control. M2: 1-kb size marker.
The PCR primers for PCR and size of PCR products
| Primer | Target | DNA sequence (5' to 3') | Product Sizesize | Note |
|---|---|---|---|---|
| Tem-F | GAAGATCAGTTGGGTGCACGAGT | 550 bp | This study | |
| Tem-R | CAACTTTATCCGCCTCCATCCAGT | |||
| STR-F1 | AGACGCTCCGCGCTATAGAAGT | 203 bp | (46) | |
| STR-R1 | CGGACCTACCAAGGCAACGCT | |||
| CS-F | GGCATCCAAGCAGCAAG | Variable | (47) | |
| CS-R | AAGCAGACTTGACCTGA | |||
| 1.9CS-F | CTGCTGCGTAACATCGTTGCT | Variable | This study | |
| 1.9CS-R | GGCGAGATCATCAAGTCAGT | |||
| ColE1-F | ColE1 | CAAATGCTGTCCTTCCAGTGT | 225 bp | This study |
| ColE1-R | CTCAGTTCGGTGTAGGTCGT | |||
| F-F | Inc | CAACAACGCGCCGACACCGT | 288 bp | This study |
| F-R | CCCTTCCTGTCGACGCTTCT | |||
| R100-F | Inc | CCACCAAAAGCACCACACACT | 266 bp | This study |
| R100-R | AGACACTCCTAGCAGCGCCT | |||
| pSC138-F | Inc | TGTCACGAACATCTGCCAGT | 193 bp | This study |
| pSC138-R | GAGAGAAAGTGCCCATGGCT | |||
| IS26in-F | GGCACTGTTGCAAAGTTAGC | 820 bp | DQ390455.1 | |
| IS26in-R | GGCACTGTTGCAAATAGTCG | |||
| IS26out-F | Variable | GCTAACTTTGCAACAGTGCC | Variable | DQ390455.1 |
| IS26out-R | CGACTATTTGCAACAGTGCC | |||
| Tn-F | Tn | ACCTAGATTCTACGTCAGTAC | Variable | (35) |
| AmpC-F | AmpC | CAAGTTTGATTCCTTGGACTCT | AY253913 | |
| AmpC-R | CTCATCGTCAGTTATTGCAGCT | |||
| SugE-R | GCCTGATATGTCCTGGATCGT |